Диссертация (Факторы риска формирования неблагоприятных исходов хронического гепатита С), страница 19

Increasing mortality due to end-stage liverdisease in patients with human immunodeficiency virus infection // Clin. Infect.Dis. – 2001. – Vol. 32. – № 3. – P. 492-497.47. Bisceglie A., Sterling R., Chung R. Serum alpha-fetoprotein levels in patientswith advanced hepatitis C: results from the HALT-C Trial // J. Hepatol. – 2005.

–Vol. 43. – № 3. – P. 434-441.48. Bosch F., Ribes J., Díaz M. et al. Primary liver cancer: worldwide incidenceand trends // Gastroenterology – 2004. – Vol. 127. – № 5. – Suppl 1. – P. S5-S16.49. Bravi F., Tavani A., Bosetti C. et al. Coffee and the risk of hepatocellularcarcinoma and chronic liver disease // Eur. J. Cancer Prev. – 2017. – Vol. 26. – №5. – P.368-377.50. Bruix J., Sherman M.

Management of hepatocellular carcinoma: An update //Hepatology – 2011. – Vol. 53. – № 3. – P. 1020-1022.51. Bruno S., Crosignani A., Facciotto C. et al. Sustained virologic responseprevents the development of esophageal varices in compensated, Child-Pugh classA hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study //Hepatology – 2010. – Vol.

51. – № 6. – P. 2069- 2076.52. Bruno S., Crosignani A., Maisonneuve P. et al. Hepatitis C virus genotype 1bas a major risk factor associated with hepatocellular carcinoma in patients withcirrhosis: a seventeen-year prospective cohort study // Hepatology – 2007. – Vol.46. – № 5. – P. 1350-1356.53. Bruno S., Marco V., Iavarone M. et al. Survival of patients with HCV cirrhosisand sustained virologic response is similar to the general population // J.

Hepatol. –2016. – Vol. 64. – № 6. – P. 1217-1223.54. Bruno S., Saibeni S., Bagnardi V. et al. Mortality risk according to differentclinical characteristics of first episode of liver decompensation in cirrhotic patients:a nationwide, prospective, 3-year follow-up study in Italy // Am. J. Gastroenterol.– 2013. – Vol. 108. – № 7. – P. 1112-1122.55. Bruno S., Silini E., Crosignani A.

et al. Hepatitis C virus genotypes and risk of122hepatocellular carcinoma in cirrhosis: A prospective study // Hepatology – 1997. –Vol. 25. – № 3. – P. 754-758.56. Bruno S., Stroffolini T., Colombo M. et al. Sustained virological response tointerferon-alpha is associated with improved outcome in HCV-related cirrhosis: aretrospective study // Hepatology – 2007. – Vol. 45. – № 3. – P. 579-587.57. Bruno S., Zuin M., Crosignani A. et al. Predicting mortality risk in patientswith compensated HCV-induced cirrhosis: A long-term prospective study // Am. J.Gastroenterol. – 2009.

– Vol. 104. – № 5. – P. 1147-1157.58. Cacoub P., Comarmond C. New insights into HCV-related rheumatologicdisorders: A review // J. Adv. Res. – 2017. – Vol. 8. – № 2. – P. 89-97.59. Calvaruso V., Marco V., Bavetta M. et al. Quantification of fibrosis bycollagen proportionate area predicts hepatic decompensation in hepatitis Ccirrhosis // Aliment. Pharmacol. Ther. – 2015. – Vol. 41. – № 5. – P. 477-486.60. Calzadilla-Bertot L., Vilar-Gomez E., Torres-Gonzalez A.

et al. Impairedglucose metabolism increases risk of hepatic decompensation and death in patientswith compensated hepatitis C virus-related cirrhosis // Dig. Liver Dis. – 2016. –Vol. 48. – № 3. – P. 283-290.61. Cammà C., Petta S., Marco V. et al. Insulin resistance is a risk factor foresophageal varices in hepatitis C virus cirrhosis // Hepatology – 2009. – Vol. 49. –№ 1. – P. 195-203.62.

Cardoso A.-C., Moucari R., Figueiredo-Mendes C. et al. Impact ofpeginterferon and ribavirin therapy on hepatocellular carcinoma: incidence andsurvival in hepatitis C patients with advanced fibrosis // J. Hepatol. – 2010. – Vol.52. – № 5. – P.

652-657.63. Chang K.-C., Hung C.-H., Lu S.-N. et al. A novel predictive score forhepatocellular carcinoma development in patients with chronic hepatitis C aftersustained response to pegylated interferon and ribavirin combination therapy // J.Antimicrob. Chemother. – 2012. – Vol. 67. – № 11. – P. 2766-2772.64. Chang K.-C., Tseng P.-L., Wu Y.-Y. et al. A polymorphism in interferon L3 isan independent risk factor for development of hepatocellular carcinoma after123treatment of hepatitis C virus infection // Clin. Gastroenterol.

Hepatol. – 2015. –Vol. 13. – № 5. – P. 1017-1024.65. Chen C.-L., Yang H.-I., Yang W.-S. et al. Metabolic factors and risk ofhepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study inTaiwan // Gastroenterology – 2008.

– Vol. 135. – № 1. – P. 111-121.66. Chen K.-J., Fan F., Wang Y. et al. GSTT1 null genotype contributes tohepatocellular carcinoma risk: a meta-analysis // Tumor Biol. – 2014. – Vol. 35. –№ 1. – P. 213-218.67. Cho L., Yang J., Ko K.-P. et al. Coinfection of hepatitis B and C viruses andrisk of hepatocellular carcinoma: systematic review and meta-analysis // Int. J.cancer – 2011. – Vol. 128. – № 1. – P. 176-184.68.

Christensen P., Hay G., Jepsen P. et al. Hepatitis C prevalence in Denmark -anestimate based on multiple national registers // BMC Infect. Dis. – 2012. – №12. –P. 1-8.69. Chuang S.-C., Lee Y.-C., Hashibe M. et al. Interaction between cigarettesmoking and hepatitis B and C virus infection on the risk of liver cancer: a metaanalysis // Cancer Epidemiol. Biomarkers Prev.

– 2010. – Vol. 19. – № 5. – P.1261-1268.70. Chung R., Davis G., Jensen D. et al. Hepatitis C guidance: AASLD-IDSArecommendations for testing, managing, and treating adults infected with hepatitisC virus // Hepatology – 2015. – Vol. 62. – № 3. – P. 932-954.71. Colecchia A., Colli A., Casazza G. et al. Spleen stiffness measurement canpredict clinical complications in compensated HCV-related cirrhosis: Aprospective study // J. Hepatol. – 2014. – Vol. 60. – № 6. – P. 1158-1164.72.

Corrao G., Aricò S. Independent and combined action of hepatitis C virusinfection and alcohol consumption on the risk of symptomatic liver cirrhosis //Hepatology – 1998. – Vol. 27. – № 4. – P. 914-919.73. Cromie S., Jenkins P., Bowden D. et al. Chronic hepatitis C: effect of alcoholon hepatitic activity and viral titre // J. Hepatol. – 1996. – Vol. 25. – № 6. – P. 821826.12474. D’Ambrosio R., Aghemo A., Rumi M. et al.

The course of esophageal varicesin patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy //Antivir. Ther. – 2011. – Vol. 16. – № 5. – P. 677-684.75. D’Ambrosio R., Aghemo A., Rumi M. et al. A morphometric andimmunohistochemical study to assess the benefit of a sustained virologicalresponse in hepatitis C virus patients with cirrhosis // Hepatology – 2012. – Vol.56. – № 2. – P. 532-543.76. D’Amico G., Caltagirone M., Malizia G. et al. Competing risks and prognosticstages of cirrhosis: A 25-year inception cohort study of 494 patients // Aliment.Pharmacol. Ther.

– 2014. – Vol. 39. – № 10. – P. 1180-1193.77. Dammacco F. The cryoglobulins: An overview // Eur. J. Clin. Invest. – 2001. –Vol. 31. – № 7. – P. 628-638.78. Davila J., Morgan R., Shaib Y. et al. Diabetes increases the risk ofhepatocellular carcinoma in the United States: a population based case controlstudy // Gut – 2005. – Vol. 54. – № 4. – P. 533-539.79. Davis G., Alter M., El-Serag H. et al. Aging of Hepatitis C Virus (HCV)Infected Persons in the United States: A Multiple Cohort Model of HCVPrevalence and Disease Progression // Gastroenterology – 2010.

– Vol. 138. – № 2.– P. 513-521.80. Degos F., Christidis C., Ganne-Carrie N. et al. Hepatitis C virus relatedcirrhosis: time to occurrence of hepatocellular carcinoma and death // Gut – 2000.– Vol. 47. – № 1. – P. 131-136.81. Donato F., Boffetta P., Puoti M. A meta-analysis of epidemiological studies onthe combined effect of hepatitis B and C virus infections in causing hepatocellularcarcinoma // Int. J. cancer – 1998. – Vol. 75. – № 3. – P. 347-354.82. Donato F., Tagger A., Gelatti U.

et al. Alcohol and hepatocellular carcinoma:the effect of lifetime intake and hepatitis virus infections in men and women // Am.J. Epidemiol. – 2002. – Vol. 155. – № 4. – P. 323-331.83. El-Serag H. Epidemiology of viral hepatitis and hepatocellular carcinoma //Gastroenterology – 2012. – Vol. 142.

– № 6. – P. 1264-1273.12584. El-Serag H., Hampel H., Javadi F. The association between diabetes andhepatocellular carcinoma: a systematic review of epidemiologic evidence // Clin.Gastroenterol. Hepatol. – 2006. – Vol. 4. – № 3. – P. 369-380.85. El-Serag H., Kanwal F. Obesity and hepatocellular carcinoma: Hype andreality // Hepatology – 2014. – Vol. 60. – № 3.

– P. 779-781.86. El-Serag H., Kanwal F., Davila J. et al. A new laboratory-based algorithm topredict development of hepatocellular carcinoma in patients with hepatitis C andcirrhosis // Gastroenterology – 2014. – Vol. 146. – № 5. – P. 1249-1255.87. El-Serag H., Kanwal F., Richardson P. et al. Risk of hepatocellular carcinomaafter sustained virological response in Veterans with hepatitis C virus infection //Hepatology – 2016. – Vol. 64. – № 1. – P. 130-137.88. Elkrief L., Chouinard P., Bendersky N. et al. Diabetes mellitus is anindependent prognostic factor for major liver-related outcomes in patients withcirrhosis and chronic hepatitis C // Hepatology – 2014. – Vol. 60.

– № 3. – P. 823831.89. Elsayed E., Mosalam N., Mohamed N. Resistin and Insulin Resistance: A LinkBetween Inflammation and Hepatocarcinogenesis // Asian Pac. J. Cancer Prev. –2015. – Vol. 16. – № 16. – P. 7139-7142.90. European Association For The Study Of The Liver EASL-EORTC clinicalpractice guidelines: management of hepatocellular carcinoma / EuropeanAssociation For The Study Of The Liver, European Organisation For ResearchAnd Treatment Of Cancer // J. Hepatol.

– 2012. – Vol. 56. – № 4. – P. 908-943.91. Fabris C., Falleti E., Cussigh A. et al. IL-28B rs12979860 C/T alleledistribution in patients with liver cirrhosis: role in the course of chronic viralhepatitis and the development of HCC // J. Hepatol. – 2011. – Vol. 54. – № 4. – P.716-722.92. Fattovich G., Giustina G., Degos F. et al. Morbidity and mortality incompensated cirrhosis type C: a retrospective follow-up study of 384 patients //Gastroenterology – 1997. – Vol. 112.